This page lists the cancer care hospitals in our directory offering Bile Duct Cancer Treatment in Hyderabad, India, including KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills. Each listing links through to the hospital's full profile page.
Ask us about bile duct cancer treatment in Hyderabad, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 4 accredited hospitals for Cancer Care in Hyderabad, India
Featured🇮🇳 KIMS Hospitals, Secunderabad
Ranks #1 in this list by listed rating (4.8/5 from 743 reviews).
🇮🇳 Yashoda Hospitals, Secunderabad
Ranks #2 in this list by listed rating (4.7/5 from 518 reviews).
🇮🇳 Apollo Hospital DRDO
Ranks #3 in this list by listed rating (4.5/5 from 82 reviews).
🇮🇳 Apollo Hospitals, Jubilee Hills
Ranks #4 in this list by listed rating (4.1/5 from 44 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Bile Duct Cancer Treatment in Hyderabad, India?
Choosing the right hospital for bile duct cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Bile Duct Cancer Treatment
Bile duct cancer (cholangiocarcinoma) is a rare but aggressive malignancy arising from the epithelial cells lining the biliary tract, requiring a highly specialized multidisciplinary approach that integrates hepatobiliary surgery, interventional oncology, and precision medicine. With curative resection rates of 25–40% in resectable cases and improving 5-year survival outcomes through advanced targeted therapies such as IDH1 inhibitors and FGFR2 inhibitors, patients worldwide are achieving better results at internationally accredited centers. GAF Healthcare connects international patients with leading JCI- and NABH-accredited oncology hospitals in India and JCI- and DHA-accredited centers in the UAE, offering expert-level biliary oncology care at a fraction of Western costs, with comprehensive end-to-end medical tourism coordination. Hospital Stay: 10–21 days (varies by surgical complexity and adjuvant treatment phase) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (longer for major hepatic resection; shorter for palliative stenting or systemic therapy initiation) • Success Rate: Curative resection: 25–40% long-term disease-free survival; palliative/systemic therapy disease control rate: 50–65%
Clinical Overview
Cholangiocarcinoma (bile duct cancer) originates from cholangiocytes — the epithelial cells lining the intrahepatic, perihilar (Klatskin tumor), or distal extrahepatic bile ducts. It is classified anatomically as intrahepatic (iCCA), perihilar (pCCA), or distal cholangiocarcinoma (dCCA), each with distinct surgical approaches, staging systems, and molecular profiles. The Bismuth-Corlette classification remains the cornerstone for stratifying perihilar tumors (Types I–IV), directly determining resectability and the extent of hepatic resection required. Physiologically, tumor growth causes progressive biliary obstruction, leading to cholestasis, jaundice, pruritis, malabsorption of fat-soluble vitamins, coagulopathy due to impaired vitamin K absorption, and, in advanced cases, biliary sepsis and liver failure. Elevated serum bilirubin, alkaline phosphatase, CA 19-9, and CEA are common biochemical hallmarks, though CA 19-9 lacks specificity and must be interpreted alongside cross-sectional imaging. The standard diagnostic workup encompasses multiphasic contrast-enhanced CT (CECT) of the chest, abdomen, and pelvis; magnetic resonance cholangiopancreatography (MRCP) for biliary anatomy delineation; PET-CT for nodal and distant metastasis assessment; and endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) for tissue biopsy and biliary drainage. Next-generation sequencing (NGS) of tumor tissue or cell-free DNA (liquid biopsy) is now standard to identify actionable mutations — particularly FGFR2 fusions/rearrangements (present in ~15% of iCCA), IDH1 mutations (~20% of iCCA), BRAF V600E, HER2 amplification, and microsatellite instability (MSI-H) — which directly guide targeted therapy and immunotherapy eligibility. The global standard of care is determined by disease stage and resectability. For resectable disease, en bloc surgical resection with negative (R0) margins is the only potentially curative option, often requiring major hepatectomy, bile duct excision, and regional lymphadenectomy, with or without vascular reconstruction. Adjuvant capecitabine chemotherapy (per BILCAP trial data) for 6 months is now recommended post-resection. For unresectable or metastatic disease, the first-line standard shifted significantly with the TOPAZ-1 trial, establishing gemcitabine plus cisplatin plus durvalumab (anti-PD-L1) as the new benchmark, improving median overall survival to approximately 12.8 months. Targeted agents — pemigatinib or futibatinib for FGFR2 fusions, ivosidenib for IDH1-mutant CCA, pembrolizumab for MSI-H/TMB-H tumors — are deployed in second-line and beyond based on molecular profiling.
Who is a Candidate?
• ELIGIBLE FOR SURGICAL RESECTION (Curative Intent): • Patients with anatomically resectable intrahepatic, perihilar, or distal bile duct tumors confirmed on MRCP and CECT • Adequate future liver remnant (FLR): minimum 25–30% in normal liver, 40% in cirrhotic or post-chemotherapy liver (assessed by volumetric CT) • No radiological evidence of distant metastases on PET-CT • ECOG Performance Status 0–1 • Biliary drainage achieved pre-operatively to normalize bilirubin (target <2 mg/dL before major hepatectomy) • Child-Pugh Class A hepatic function; MELD score assessed to stratify surgical risk • Portal vein embolization (PVE) candidates when FLR is insufficient to allow hypertrophy before resection • ELIGIBLE FOR SYSTEMIC/TARGETED THERAPY: • Unresectable locally advanced or metastatic cholangiocarcinoma • Adequate organ function: ANC ≥1,500/µL, creatinine clearance ≥45 mL/min, bilirubin ≤1.5× ULN • FGFR2 fusion/rearrangement positive: eligible for pemigatinib or futibatinib • IDH1 mutation positive: eligible for ivosidenib • MSI-H / dMMR / TMB-H: eligible for pembrolizumab • HER2-amplified: eligible for trastuzumab-based combinations (investigational/select centers) • ECOG Performance Status 0–2 • ELIGIBLE FOR LIVER TRANSPLANTATION (Highly Selected pCCA): • Unresectable perihilar CCA meeting Mayo Clinic protocol criteria: tumor ≤3 cm radial diameter, no intrahepatic or extrahepatic metastases, no prior transperitoneal biopsy, completion of neoadjuvant chemoradiation • REQUIRED DIAGNOSTIC TESTS: • Multiphasic CECT (chest, abdomen, pelvis) • MRCP (biliary anatomy and tumor extent) • PET-CT (nodal/distant metastasis staging) • ERCP/PTC with brush cytology or forceps biopsy for histological confirmation • Liver volumetry (CT-based) if major hepatectomy planned • Next-generation sequencing (NGS) panel: FGFR2, IDH1/2, BRAF, HER2, NTRK, RET, MSI/MMR, TMB • Liver function tests, coagulation profile, CA 19-9, CEA, AFP • ECHO (echocardiogram) if cisplatin-based chemotherapy planned (cardiac baseline) • HBV/HCV serology, HIV, complete blood count, metabolic panel • CONTRAINDICATIONS / HIGH-RISK EXCLUSIONS: • Bilobar hepatic metastases or peritoneal carcinomatosis • Bilateral hepatic arterial and portal venous involvement precluding R0 resection • ECOG Performance Status ≥3 or Karnofsky score <60 • Severe hepatic dysfunction: Child-Pugh B/C or MELD >15 (for surgical candidates) • Uncontrolled biliary sepsis prior to stabilization • Active autoimmune disease requiring systemic immunosuppression (relative contraindication for immunotherapy)
Treatment Options & Approaches
SURGICAL APPROACHES (Curative Intent): 1. Extended Hepatectomy with Bile Duct Excision (Perihilar / Intrahepatic CCA): The most complex hepatobiliary procedure, involving right or left hepatectomy (often extended to segments I, IV, V, VIII), complete extrahepatic bile duct excision, regional lymphadenectomy, and Roux-en-Y hepaticojejunostomy reconstruction. Vascular resection and reconstruction of the portal vein or hepatic artery may be required in select Bismuth-Corlette Type III/IV tumors. The caudate lobe (segment I) is routinely resected for perihilar CCA given its dual biliary drainage. Intraoperative frozen section analysis of bile duct margins is mandatory to confirm R0 status. 2. Pancreaticoduodenectomy / Whipple Procedure (Distal CCA): For distal extrahepatic cholangiocarcinoma, a classic or pylorus-preserving pancreaticoduodenectomy (PPPD) is performed, achieving R0 resection of the distal bile duct en bloc with the pancreatic head, duodenum, and regional lymph nodes. Minimally invasive and robotic-assisted Whipple procedures are now performed at high-volume centers, offering reduced blood loss, faster return of bowel function, and shorter hospital stays versus open surgery, without compromising oncological outcomes. 3. Robotic-Assisted and Laparoscopic Hepatectomy: Robotic platforms (da Vinci Xi) and advanced laparoscopic techniques are increasingly used for anatomic liver resections in intrahepatic CCA, particularly for anterolateral segments. Benefits include magnified 3D visualization, precision in parenchymal transection, and reduced postoperative morbidity. Intraoperative ultrasound (IOUS) is used in all cases to confirm tumor-free margins in real time. 4. Portal Vein Embolization (PVE) + Staged Hepatectomy: In patients with insufficient future liver remnant, percutaneous portal vein embolization of the tumor-bearing lobe is performed 4–6 weeks prior to resection, inducing compensatory hypertrophy of the contralateral lobe. Liver volume response is reassessed by CT volumetry before proceeding. 5. Liver Transplantation (Highly Selected pCCA): Following the Mayo Clinic protocol, carefully selected patients with unresectable perihilar CCA undergo neoadjuvant external beam radiotherapy (45 Gy in 30 fractions) with concurrent 5-fluorouracil sensitization, followed by brachytherapy boost and systemic capecitabine, before orthotopic liver transplantation. 5-year survival rates of 65–70% have been reported in this selected cohort. INTERVENTIONAL / LOCOREGIONAL THERAPIES: 6. Biliary Drainage (ERCP / PTC with Stenting): Essential for relieving biliary obstruction prior to surgery or as palliation. Self-expanding metal stents (SEMS) are preferred over plastic stents for malignant obstruction given longer patency. For perihilar tumors requiring bilateral drainage, combined endoscopic-percutaneous approaches or bilateral plastic stenting may be employed. 7. Transarterial Chemoembolization (TACE) / Transarterial Radioembolization (TARE / Y-90 SIRT): For unresectable intrahepatic CCA with liver-dominant disease, hepatic artery-based therapies deliver locoregional tumor control. TARE using Yttrium-90 microspheres (TheraSphere or SIR-Spheres) has shown objective response rates of 25–35% in iCCA, serving as a bridge to resection or transplant in select cases. 8. Irreversible Electroporation (IRE / NanoKnife): A non-thermal ablation technique applicable for CCA tumors abutting major bile ducts or hepatic vessels where thermal ablation (RFA/MWA) would be unsafe. IRE delivers high-voltage electrical pulses causing cell membrane disruption while preserving ductal and vascular architecture. 9. Photodynamic Therapy (PDT) with Biliary Stenting: For unresectable perihilar CCA, endoscopic PDT using porfimer sodium or temoporfin activated by 630 nm laser light delivered via ERCP improves biliary patency, reduces cholangitis episodes, and has demonstrated survival benefit over stenting alone in randomized trials. SYSTEMIC THERAPIES: 10. First-Line Chemotherapy + Immunotherapy: Gemcitabine (1,000 mg/m² Days 1,8) + Cisplatin (25 mg/m² Days 1,8) + Durvalumab (1,500 mg Day 1) every 21 days (TOPAZ-1 regimen) is the current global first-line standard for advanced/metastatic CCA, with a 24-month OS rate of approximately 24.9% vs. 10.4% with chemotherapy alone. 11. Second-Line Targeted Therapies: • FGFR2 fusion/rearrangement: Pemigatinib (13.5 mg orally once daily, 2 weeks on/1 week off) or Futibatinib (20 mg orally once daily, continuous); ORR ~35% • IDH1 mutation: Ivosidenib (500 mg orally once daily); median PFS 2.7 months vs. 1.4 months placebo (ClarIDHy trial) • MSI-H / TMB-H: Pembrolizumab monotherapy; ORR ~40% in MSI-H solid tumors • BRAF V600E: Dabrafenib + Trametinib combination • NTRK fusion: Larotrectinib or Entrectinib 12. Adjuvant Chemotherapy: Capecitabine 1,250 mg/m² twice daily (Days 1–14 of each 21-day cycle) for 8 cycles (24 weeks) post-R0 or R1 resection, per BILCAP trial, demonstrated improved overall survival in the per-protocol analysis. RADIATION THERAPY: Stereotactic Body Radiotherapy (SBRT) delivers ablative doses (40–60 Gy in 3–6 fractions) to intrahepatic CCA tumors or oligometastatic sites with high precision using real-time image guidance, minimizing hepatic parenchymal injury. Intensity-modulated radiotherapy (IMRT) and proton beam therapy are used for perihilar tumors where sparing of the duodenum, stomach, and spinal cord is critical.
Recovery
PRE-OPERATIVE / PRE-TREATMENT PHASE (Weeks 1–4 before intervention): Step 1 — Remote Case Evaluation (Before Travel): Patient submits existing imaging (CT, MRI, MRCP, PET-CT), histopathology reports, blood work, and operative records (if any) to GAF Healthcare. Assigned hepatobiliary oncology multidisciplinary team (MDT) reviews the case. A detailed second-opinion report, treatment plan, and itemized cost estimate are provided within 72 hours. Step 2 — Visa and Travel Coordination: GAF Healthcare initiates e-Medical Visa application for India (typically approved in 3–5 working days) or entry visa / visa-on-arrival arrangements for the UAE. Arrival logistics including airport transfers, accommodation for patient and attendant, and SIM cards with local emergency contacts are arranged. Step 3 — Arrival and In-Hospital Workup (Days 1–5): Comprehensive pre-treatment evaluation including repeat CECT/MRCP if recent imaging is unavailable, PET-CT, liver volumetry, NGS panel (FGFR2, IDH1, BRAF, MSI/MMR), ECHO, pulmonary function tests, nutritional assessment, and anesthesia fitness review. Biliary drainage (ERCP/PTC stenting) is performed if obstructive jaundice is present, with a minimum 2-week drainage period before major hepatectomy to allow bilirubin normalization and hepatic function recovery. MDT conference finalizes treatment strategy. Step 4 — Nutritional and Performance Optimization: Hepatic surgery imposes significant metabolic demands. Patients receive preoperative immunonutrition (arginine, omega-3 fatty acids, glutamine) for 5–7 days, correction of coagulopathy with parenteral Vitamin K, and targeted physiotherapy to optimize cardiopulmonary reserve. INTRA-OPERATIVE PHASE (Day of Surgery / Procedure): Step 5 — Surgical or Interventional Procedure: For resectable cases: general anesthesia, intraoperative ultrasound, anatomic hepatectomy with bile duct excision and Roux-en-Y reconstruction, or Whipple procedure for distal CCA. Operating time: 4–10 hours depending on complexity. Estimated blood loss is managed with cell salvage technology. Intraoperative cholangiography confirms biliary reconstruction integrity. For interventional procedures (TACE/TARE/IRE/PDT): performed under conscious sedation or general anesthesia in the interventional radiology suite; duration 1–3 hours. For systemic therapy initiation: day-care infusion setting; Cycle 1 Day 1 of gemcitabine-cisplatin-durvalumab administered with pre-medications (ondansetron, dexamethasone, G-CSF support as clinically indicated). POST-OPERATIVE / POST-PROCEDURE PHASE: Step 6 — ICU / HDU Monitoring (Days 1–3 post-surgery): Hemodynamic monitoring, liver function trend analysis (serum bilirubin, INR, transaminases daily — the International Study Group of Liver Surgery [ISGLS] criteria used for post-hepatectomy liver failure [PHLF] grading), biliary drain output monitoring, DVT prophylaxis with low molecular weight heparin, early nasojejunal feeding commenced within 24–48 hours. Step 7 — Ward Recovery (Days 3–10 post-surgery): Progressive ambulation, transition from enteral to oral nutrition, drain removal when output <100 mL/day with non-bilious fluid, wound care, and pain management with multimodal analgesia (epidural or IV PCA transitioned to oral). Post-Whipple patients monitored for delayed gastric emptying, pancreatic fistula (POPF — ISGP grading), and bile leak. Step 8 — Oncological Review and Adjuvant Planning (Days 10–14): Final histopathology confirming R status (R0/R1/R2), lymph node involvement, perineural invasion, and vascular invasion. MDT review of NGS results. Adjuvant capecitabine scheduled if appropriate; initiation typically begins 6–8 weeks post-surgery. PET-CT baseline scan for systemic therapy patients prior to Cycle 2. Step 9 — Discharge and Transition (Days 14–21): Patient discharged with detailed discharge summary, wound care instructions, medication reconciliation, dietary guidelines (low-fat diet post-Whipple; high-calorie, high-protein diet post-hepatectomy), and scheduled outpatient oncology follow-up. Biliary drainage catheters (if any PTC drains remain) are managed by a local interventional radiologist in the home country with GAF-facilitated telemedicine follow-up. POST-DISCHARGE / FIT-TO-FLY MILESTONES: Step 10 — Recovery Milestones Before Flying: • Minor procedures (biliary stenting, chemotherapy initiation, PDT): fit to fly in 1–2 weeks pending clinical stability. • Locoregional therapies (TACE, TARE, IRE): fit to fly in 2–3 weeks after confirming absence of post-embolization syndrome and biloma. • Major hepatectomy or Whipple procedure: fit to fly in 6–8 weeks, subject to: bilirubin normalization, absence of bile leak, adequate oral intake, wound healing, and physician clearance. Long-haul flights require prophylactic low molecular weight heparin given elevated VTE risk in cancer surgery patients. Step 11 — Long-Term Surveillance: Every 3 months for 2 years: CECT chest-abdomen-pelvis, CA 19-9, CEA, LFTs. Annual MRCP for anastomotic stricture assessment post-hepaticojejunostomy. Telemedicine consultations with treating surgeon and oncologist via GAF Healthcare's virtual follow-up platform.
Risks to be aware of
Bile duct cancer treatment carries a spectrum of procedure-specific and oncology-related risks that must be contextualized honestly. For major hepatectomy and bile duct excision, the most serious risks include post-hepatectomy liver failure (PHLF) — occurring in up to 8–10% of extended resections — which carries significant mortality if ISGLS Grade C is reached; bile leak (Grade B/C in 5–15% of cases, requiring percutaneous drainage or re-exploration); post-operative biliary stricture at the hepaticojejunostomy anastomosis (long-term risk of 5–10%); intra-abdominal hemorrhage; and septic cholangitis. Pancreaticoduodenectomy for distal CCA carries the additional risks of delayed gastric emptying (DGE, 15–25%), post-operative pancreatic fistula (POPF, 10–20%), and marginal ulceration. Perioperative mortality at high-volume centers is approximately 2–5% for major hepatic resections. For systemic therapies, the gemcitabine-cisplatin-durvalumab combination carries risks of nephrotoxicity (cisplatin-mediated — renal function monitored before each cycle), myelosuppression with febrile neutropenia risk (~15%), immune-mediated adverse events from durvalumab (pneumonitis, hepatitis, endocrinopathies in 10–15% of patients, most Grade 1–2), and peripheral neuropathy with prolonged cisplatin exposure. Targeted agents such as pemigatinib and futibatinib carry the class-specific risk of hyperphosphatemia and soft tissue mineralization requiring dietary phosphate restriction. Ivosidenib may cause QTc prolongation requiring baseline and on-treatment ECG monitoring. For locoregional therapies, post-embolization syndrome (fever, pain, nausea following TACE/TARE) occurs in the majority of patients and is self-limiting within 5–7 days; biloma formation, hepatic abscess, and radiation-induced liver disease (RILD) following Y-90 SIRT are less common but serious complications occurring in 3–8% of cases. Biliary stenting carries risks of cholangitis, stent occlusion, and stent migration. Patients considering surgery should also be counseled that even technically successful R0 resection does not guarantee cure — perihilar CCA has a 5-year survival of approximately 20–40% post-resection, and recurrence (intrahepatic or metastatic) within 2 years occurs in more than 50% of cases. Ongoing surveillance and adjuvant therapy are therefore non-optional components of the treatment continuum.
Why GAF Healthcare
GAF Healthcare provides comprehensive non-medical coordination services that begin the moment a patient initiates contact and continue through long-term post-treatment follow-up, regardless of whether the destination is India or the UAE. VISA AND ENTRY SUPPORT: • India: GAF Healthcare facilitates the e-Medical Visa (e-MV) application for the patient and up to two attendants. The e-MV is granted for a triple-entry stay of up to 60 days per visit and is typically approved within 3–5 working days online via the Indian government's e-Visa portal. GAF provides hospital invitation letters and cost estimates required as supporting documentation. Extensions are facilitated through FRRO (Foreigners Regional Registration Office) for patients requiring prolonged treatment. • UAE (Dubai / Abu Dhabi): Citizens of over 50 countries receive visa-on-arrival or visa-free access to the UAE for 30–90 days. For other nationalities, GAF coordinates the UAE medical treatment visa or tourist visa application in advance. The UAE's geographic position — within a 4–6 hour flight of most of Africa, South Asia, and the Middle East — makes it an exceptionally accessible destination. AIRPORT AND GROUND TRANSFERS: Dedicated GAF patient coordinators arrange airport reception with name-board pickup, wheelchair-accessible vehicles for mobility-impaired patients, and direct transfer to the hospital or accommodation. Return transfers and inter-facility transfers (e.g., hotel to hospital for outpatient chemotherapy) are included in the coordination package. ACCOMMODATION: For patients requiring multiple chemotherapy cycles or extended recovery periods, GAF arranges serviced apartments or partner hotels within 2–5 km of the treating hospital — with access to Indian or international cuisine to accommodate dietary requirements, particularly the low-fat, high-protein diet critical for post-hepatectomy recovery. Attendant accommodation is arranged in the same facility. Laundry, housekeeping, and 24-hour security are standard. DEDICATED INTERPRETERS AND COORDINATORS: GAF provides certified medical interpreters for Arabic, Russian, French, Swahili, and other languages — present during all major consultations, surgical consent discussions, and MDT meetings. A single dedicated case manager is assigned per patient, serving as the primary point of contact for all medical and logistical queries throughout the journey. TELEMEDICINE AND REMOTE FOLLOW-UP: Post-discharge, GAF facilitates monthly telemedicine video consultations with the treating hepatobiliary surgeon and oncologist, with structured templates for local laboratory results, imaging uploads, and medication reconciliation — ensuring continuity of care after the patient returns home. FINANCIAL TRANSPARENCY: GAF provides a fully itemized, no-obligation cost estimate before the patient travels, with clarity on what is and is not included. Transparent billing at partner hospitals eliminates surprise charges. For systemic therapy patients, drug cost estimates are provided based on the patient's specific molecular profile and regimen.
Common questions about Bile Duct Cancer Treatment
What is the cost of Bile Duct Cancer Treatment in India vs the UAE?
How long do I need to stay in the country before I am fit to fly home after Bile Duct Cancer Treatment?
What is the success rate of Bile Duct Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Bile Duct Cancer Treatment in Hyderabad, India
Discover the Top Hospitals for Bile Duct Cancer Treatment in Hyderabad, India
This page lists 4 accredited cancer care hospitals in Hyderabad, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about bile duct cancer treatment in Hyderabad, India
How many cancer care hospitals are listed in Hyderabad, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there cancer care hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for bile duct cancer treatment in Hyderabad, India.
Contact us to report an inaccuracy on this page.